| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.00 [0.80, 1.25] | | < 1 | | 0% | 2 studies (2/-) | 50.0 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.01 [0.60, 1.71] | | < 1 | | 89% | 3 studies (3/-) | 48.4 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.51 [0.98, 2.34] | | > 1 | | 0% | 3 studies (3/-) | 96.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.80 [0.34, 1.87] | | < 1 | | 3% | 3 studies (3/-) | 70.0 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.54 [0.26, 1.15] | | < 1 | | 82% | 3 studies (3/-) | 94.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.79 [0.32, 1.91] | | < 1 | | 0% | 3 studies (3/-) | 70.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.23 [0.23, 6.60] | | < 1 | | 79% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.28 [0.40, 4.10] | | < 1 | | 83% | 2 studies (2/-) | 34.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.41 [0.35, 5.60] | | < 1 | | 78% | 2 studies (2/-) | 31.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.18 [0.01, 2.73] | | < 1 | | 89% | 2 studies (2/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.24 [0.07, 0.91] | | < 1 | | 93% | 3 studies (3/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.64 [0.12, 3.50] | | < 1 | | 0% | 3 studies (3/-) | 69.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 3.77 [0.17, 84.42] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.26 [0.05, 1.26] | | < 1 | | 0% | 1 study (1/-) | 95.2 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 9.63 [0.52, 177.85] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.18 [0.05, 0.66] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| Dizziness TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.20 [0.06, 0.72] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.65 [0.40, 146.03] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.88 [0.17, 20.97] | | < 1 | | 0% | 1 study (1/-) | 30.5 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.84 [0.29, 27.62] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.37 [0.24, 7.75] | | < 1 | | 0% | 2 studies (2/-) | 36.0 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.93 [0.06, 15.08] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.93 [0.13, 6.72] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.61 [0.14, 18.49] | | < 1 | | 0% | 2 studies (2/-) | 35.2 % | some concern | not evaluable | moderate | non important | - |
| Abdominal pain AE (grade 3-4) | 0.81 [0.38, 1.73] | | < 1 | | 0% | 3 studies (3/-) | 71.1 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Alopecia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.73 [0.22, 2.48] | | < 1 | | 44% | 3 studies (3/-) | 69.1 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 0.57 [0.08, 4.06] | | < 1 | | 0% | 3 studies (3/-) | 71.2 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 1.06 [0.31, 3.69] | | < 1 | | 23% | 3 studies (3/-) | 46.2 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 2.02 [0.37, 11.03] | | < 1 | | 0% | 3 studies (3/-) | 20.9 % | some concern | not evaluable | moderate | non important | - |
| Colitis AE (grade 3-4) | 1.79 [0.18, 17.83] | | < 1 | | 0% | 2 studies (2/-) | 31.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 0.90 [0.11, 7.78] | | < 1 | | 0% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 0.72 [0.07, 6.94] | | < 1 | | 0% | 3 studies (3/-) | 61.2 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.23 [0.05, 0.99] | | < 1 | | 0% | 3 studies (3/-) | 97.6 % | some concern | not evaluable | moderate | non important | - |
| Dermatitis acneiform AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.67 [0.20, 2.24] | | < 1 | | 66% | 3 studies (3/-) | 74.1 % | some concern | not evaluable | moderate | non important | - |
| Dizziness AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 0.91 [0.08, 10.12] | | < 1 | | 0% | 2 studies (2/-) | 53.0 % | some concern | not evaluable | moderate | non important | - |
| Epistaxis AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.48 [0.26, 0.90] | | < 1 | | 0% | 3 studies (3/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Headache AE (grade 3-4) | 0.90 [0.11, 7.78] | | < 1 | | 0% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 0.33 [0.06, 1.92] | | < 1 | | 83% | 3 studies (3/-) | 89.0 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.25 [0.28, 5.70] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.85 [0.23, 3.05] | | < 1 | | 0% | 3 studies (3/-) | 60.1 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Intestinal perforation AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation AE (grade 3-4) | 0.95 [0.13, 6.90] | | < 1 | | 0% | 3 studies (3/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
| Myalgia AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 0.73 [0.23, 2.28] | | < 1 | | 0% | 3 studies (3/-) | 70.6 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.06 [0.01, 0.36] | | < 1 | | 0% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.36 [0.05, 2.55] | | < 1 | | 0% | 3 studies (3/-) | 84.7 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.70 [0.10, 4.74] | | < 1 | | 0% | 3 studies (3/-) | 64.4 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 1.26 [0.11, 14.04] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritus AE (grade 3-4) | 0.56 [0.06, 4.80] | | < 1 | | 0% | 3 studies (3/-) | 70.2 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 2.72 [0.40, 18.53] | | < 1 | | 0% | 3 studies (3/-) | 15.5 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 1.05 [0.32, 3.48] | | < 1 | | 0% | 3 studies (3/-) | 47.0 % | some concern | not evaluable | moderate | non important | - |
| Rash maculopapular AE (grade 3-4) | 0.44 [0.05, 3.83] | | < 1 | | 0% | 2 studies (2/-) | 76.9 % | some concern | not evaluable | moderate | non important | - |
| Sepsis AE (grade 3-4) | 0.36 [0.07, 1.91] | | < 1 | | 0% | 2 studies (2/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis AE (grade 3-4) | 0.23 [0.03, 1.68] | | < 1 | | 0% | 3 studies (3/-) | 92.6 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.36 [0.09, 1.40] | | < 1 | | 0% | 3 studies (3/-) | 92.9 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 0.77 [0.11, 5.47] | | < 1 | | 0% | 3 studies (3/-) | 60.4 % | some concern | not evaluable | moderate | non important | - |
